These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16713103)

  • 21. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
    Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
    Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
    Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
    Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Subramanian J; Morgensztern D; Govindan R
    Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.
    Willett CG; Kozin SV; Duda DG; di Tomaso E; Kozak KR; Boucher Y; Jain RK
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S35-40. PubMed ID: 17145523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Angiogenesis inhibitors and radiation therapy: from biology to clinical practice].
    Mazeron R; Azria D; Deutsch E
    Cancer Radiother; 2009 Oct; 13(6-7):568-73. PubMed ID: 19695932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination antiangiogenic therapy and radiation in head and neck cancers.
    Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-angiogenesis targeting drugs: a review].
    Jia K; Li J
    Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New molecular targeted therapies integrated with radiation therapy in lung cancer.
    Provencio M; Sánchez A; Garrido P; Valcárcel F
    Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor and its inhibitors.
    Verheul HM; Pinedo HM
    Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.